
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp demonstrates a positive financial outlook, underscored by its stock price rising approximately 4% following recent news, reflecting market confidence. The company is viewed as undervalued, trading at around 14 times net cash, which suggests a favorable risk/reward profile as it moves through pivotal phases of drug development and potential regulatory approval. Management's successful resolution of production observations at the contract development and manufacturing organization (CDMO) facility, alongside promising Phase 3 SAPPHIRE data, enhances the prospect of regulatory approval and market expansion in the spinal muscular atrophy (SMA) space, indicating significant upside potential.
Bears say
Scholar Rock Holding Corp faces a negative outlook primarily due to the delayed launch of its lead product, apitegromab, which has resulted in lowered peak sales estimates, now projected at $1.7 billion by 2035, due to competitive risks and the establishment of new standards of care. The company has been required to push back the commercial launch dates for both the US and EU, extending timelines significantly, which reflects an operational setback and increased regulatory scrutiny following the issuance of a Complete Response Letter (CRL) from the FDA. Furthermore, continued challenges related to the SRK-181 program and heightened competitive and regulatory risks for apitegromab illustrate an uncertain market position that could negatively impact revenue growth and investor confidence moving forward.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares